Significant advances in ulcerative colitis care prompted an update to the American College of Gastroenterology (ACG) guideline for moderately to severely active disease in adults. In recent years, a ...

Merck (NYSE:MRK) reported positive Phase 3 results for tulisokibart, an anti-TL1A monoclonal antibody in moderate-to-severe ...

Researchers at Peter MacCallum Cancer Centre have developed a digital phenotype to assist with automatically identifying ...

News and commentary from the world of gastroenterology and hepatology ...

AbbVie today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®; 15 ...

The study, published in JAMA Network Open, found the relative risk for inflammatory bowel disease (IBD) was about 8% higher in kids whose mothers took prescription proton pump inhibitors (PPI) or H2 ...

Once regarded as a disease affecting people over the age of 50, colorectal cancer is now rising at an alarming rate among ...

Positive CHMP opinion is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of Severity of Alopecia Tool (SALT) score = 20 and key ...

A quiet layer of biology is beginning to change how health is understood, and it sits on the surface of nearly every cell in ...

AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of children six years of age and older with ...

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of ColoSense®, the only RNA-based at-home test for colorectal ...

By Puyaan Singh June 29 (Reuters) - Abivax said on Monday its experimental ulcerative colitis drug helped harder-to-treat groups of patients achieve remission, sending U.S.-listed shares of the ...